HopeStage
Back to all studies
CompletedNCT00191399

Olanzapine with fluoxetine for depression in bipolarity

About this title

Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response

Read the official source — NCT00191399
Medication studyAges 18+United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 18 years.

Listed locations
Seattle and 9 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMay 2004
Recruitment status
Completed
Enrollment listed in the registry
150
Sponsor
Eli Lilly and Company
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT00191399
Official title
Show the full official title

Bipolar Depression Assessment Study on Tx Response

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Seattle, United States · Bayamón, Puerto Rico · Caguas, Puerto Rico

7 more locations
  • Canovanas, Puerto Rico
  • Hato Rey, Puerto Rico
  • Manati, Puerto Rico
  • Mayagüez, Puerto Rico
  • Rio Piedras, Puerto Rico
  • San Juan, Puerto Rico
  • Santurce, Puerto Rico

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Eli Lilly and Company.

Did this study involve medication?

Yes. The study involved medication, including Olanzapine and Fluoxetine.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies